CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action
- PMID: 2865151
- DOI: 10.1007/BF00543711
CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action
Abstract
beta-Adrenoreceptor antagonists are liable to produce behavioural side-effects such as drowsiness, fatigue, lethargy, sleep disorders, nightmares, depressive moods, and hallucinations. These undesirable actions indicate that beta-blockers affect not only peripheral autonomic activity but also some central nervous mechanisms. In experimental animals beta-blockers have been found to reduce spontaneous motor activity, to counteract isolation-, lesion-, stimulation- and amphetamine-induced hyperactivity, and to produce slow-wave and paradoxical sleep disturbances. Furthermore, central effects such as tranquilizing influences are used for the treatment of conditions such as anxiety. Several different mechanisms of action could be responsible for these CNS effects: Centrally mediated specific actions on centrally located beta-adrenergic receptors, known to exist downstream from, and at the terminals of, 'vigilance-enhancing' central noradrenergic pathways. Centrally mediated specific actions on centrally located receptors of the non-adrenergic type; an affinity of some beta-blockers towards 5-HT-receptors is well documented. Centrally mediated non-specific actions on centrally located neurones, owing to the membrane-stabilizing effects of beta-blockers. Peripherally mediated actions whereby beta-blockers induce changes in the autonomic activity in the periphery, which are relayed to the CNS to induce changes in activity of a variety of central systems. It can be assumed that with any one of the beta-blockers all these mechanisms come into play, yet with varying degrees depending on characteristics of the drugs such as lipophilicity and hydrophilicity, the ratio of antagonist versus (partial) agonist properties, affinity to 'alien' receptor sites, strength of membrane-stabilizing activity, stereospecific affinity, and potency.
Similar articles
-
Central nervous system side-effects with hydrophilic and lipophilic beta-blockers.Eur J Clin Pharmacol. 1985;28 Suppl:73-6. doi: 10.1007/BF00543714. Eur J Clin Pharmacol. 1985. PMID: 2865153 Clinical Trial.
-
Psychiatric side effects of antihypertensive drugs other than reserpine.J Clin Psychopharmacol. 1982 Feb;2(1):14-39. doi: 10.1097/00004714-198202000-00004. J Clin Psychopharmacol. 1982. PMID: 6121825 Review.
-
[Hallucinations and vivid dreams by use of metoprolol].Tijdschr Psychiatr. 2010;52(2):117-21. Tijdschr Psychiatr. 2010. PMID: 20146183 Dutch.
-
Effects of two adrenergic beta-receptor blockers on the sleep cycle of the cat.Med Biol. 1978 Jun;56(3):138-43. Med Biol. 1978. PMID: 28454
-
Adverse CNS-effects of beta-adrenoceptor blockers.Pharmacopsychiatry. 1996 Nov;29(6):201-11. doi: 10.1055/s-2007-979572. Pharmacopsychiatry. 1996. PMID: 8956349 Review.
Cited by
-
CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males.Psychopharmacology (Berl). 1990;102(2):163-70. doi: 10.1007/BF02245917. Psychopharmacology (Berl). 1990. PMID: 2274600 Clinical Trial.
-
Changes in depressive status associated with topical beta-blockers.Int Ophthalmol. 1992 Sep;16(4-5):331-5. doi: 10.1007/BF00917986. Int Ophthalmol. 1992. PMID: 1428568 Clinical Trial.
-
Current Prophylactic Medications for Migraine and Their Potential Mechanisms of Action.Neurotherapeutics. 2018 Apr;15(2):313-323. doi: 10.1007/s13311-018-0621-8. Neurotherapeutics. 2018. PMID: 29671241 Free PMC article. Review.
-
(R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility.Biochem Pharmacol. 2014 Feb 15;87(4):547-61. doi: 10.1016/j.bcp.2013.11.020. Epub 2013 Dec 16. Biochem Pharmacol. 2014. PMID: 24355564 Free PMC article.
-
The enigma of site of action of migraine preventives: no effect of metoprolol on trigeminal pain processing in patients and healthy controls.J Headache Pain. 2017 Dec 19;18(1):116. doi: 10.1186/s10194-017-0827-x. J Headache Pain. 2017. PMID: 29285569 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources